|
Oncogenes and Tumor Suppressors
Citations 241-250 of 795 total displayed.
|
Past content
(since May 2000):
|
A common phosphotyrosine signature for the Bcr-Abl kinase
- Valerie L. Goss, Kimberly A. Lee, Albrecht Moritz, Julie Nardone, Erik J. Spek, Joan MacNeill, John Rush, Michael J. Comb, and Roberto D. Polakiewicz
Blood 2006; 107: 4888-4897.
[Abstract]
[Full text]
[PDF]
Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID
- Remco Dijkman, Cornelis P. Tensen, Maike Buettner, Gerald Niedobitek, Rein Willemze, and Maarten H. Vermeer
Blood 2006; 107: 4926-4929.
[Abstract]
[Full text]
[PDF]
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
- Richard D. Press, Zac Love, Ashlie A. Tronnes, Rui Yang, Thuan Tran, Solange Mongoue-Tchokote, Motomi Mori, Michael J. Mauro, Michael W. Deininger, and Brian J. Druker
Blood 2006; 107: 4250-4256.
[Abstract]
[Full text]
[PDF]
Expression of Jak2V617F causes a polycythemia vera–like disease with associated myelofibrosis in a murine bone marrow transplant model
- Gerlinde Wernig, Thomas Mercher, Rachel Okabe, Ross L. Levine, Benjamin H. Lee, and D. Gary Gilliland
Blood 2006; 107: 4274-4281.
[Abstract]
[Full text]
[PDF]
Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance
- Bao Hoang, Li Zhu, Yijiang Shi, Patrick Frost, Huajun Yan, Sanjai Sharma, Sherven Sharma, Lee Goodglick, Steven Dubinett, and Alan Lichtenstein
Blood 2006; 107: 4484-4490.
[Abstract]
[Full text]
[PDF]
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01
- Mignon L. Loh, Meredith A. Goldwasser, Lewis B. Silverman, Wing-Man Poon, Shashaank Vattikuti, Angelo Cardoso, Donna S. Neuberg, Kevin M. Shannon, Stephen E. Sallan, and D. Gary Gilliland
Blood 2006; 107: 4508-4513.
[Abstract]
[Full text]
[PDF]
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML
- Brunangelo Falini, Niccolò Bolli, Jing Shan, Maria Paola Martelli, Arcangelo Liso, Alessandra Pucciarini, Barbara Bigerna, Laura Pasqualucci, Roberta Mannucci, Roberto Rosati, Paolo Gorello, Daniela Diverio, Giovanni Roti, Enrico Tiacci, Giovanni Cazzaniga, Andrea Biondi, Suzanne Schnittger, Torsten Haferlach, Wolfgang Hiddemann, Massimo F. Martelli, Wei Gu, Cristina Mecucci, and Ildo Nicoletti
Blood 2006; 107: 4514-4523.
[Abstract]
[Full text]
[PDF]
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
- Mhairi Copland, Ashley Hamilton, Lucy J. Elrick, Janet W. Baird, Elaine K. Allan, Niove Jordanides, Martin Barow, Joanne C. Mountford, and Tessa L. Holyoake
Blood 2006; 107: 4532-4539.
[Abstract]
[Full text]
[PDF]
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide–induced apoptosis
- Paolo Lunghi, Antonio Costanzo, Luigi Salvatore, Nelida Noguera, Laura Mazzera, Antonio Tabilio, Francesco Lo-Coco, Massimo Levrero, and Antonio Bonati
Blood 2006; 107: 4549-4553.
[Abstract]
[Full text]
[PDF]
Implications of NRAS mutations in AML: a study of 2502 patients
- Ulrike Bacher, Torsten Haferlach, Claudia Schoch, Wolfgang Kern, and Susanne Schnittger
Blood 2006; 107: 3847-3853.
[Abstract]
[Full text]
[PDF]
|
|
